Associate Professor of Surgery, Case West Res University
General Surgery
Scott Wilhelm is an expert in the field of General Surgery. He graduated from University of Cincinnati College of Medicine. He over the years received 2 awards: "Regional Top Doctor" and "Fellow (FACS)". Scott M. Wilhelm, MD is a published doctor as well. He has 36 publications published. The latest was: The utility of frozen section examination for determining the extent of thyroidectomy in patients with a thyroid nodule and "atypia/follicular lesion of undetermined s... He accepts Medicare.
Publications
- The utility of frozen section examination for determining the extent of Thyroidectomy in patients with a Thyroid nodule and "atypia/follicular lesion of undetermined s...
- Evaluation of Thyroid Incidentaloma.
- Advances in management of thyroid Cancer.
- Association of Thyroid, Breast and Renal Cell Cancer: A Population-based Study of the Prevalence of Second Malignancies.
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antiTumor activity.
- Delayed mechanical small bowel Obstruction caused by retained, free, intraperitoneal staple after laparoscopic appendectomy.
- Analysis of the rising incidence of thyroid Cancer using the Surveillance, Epidemiology and End Results national Cancer data registry.
- Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves' Disease in the United States.
- Guidelines for identification and management of outpatient percutaneous endoscopic gastrostomy tube placement.
- Incidental Thyroid nodule: patterns of diagnosis and rate of malignancy.
- Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal Disease patients with hyperparathyroidism.
- Utility of I-123 Thyroid uptake scan in incidental Thyroid nodules: an old test with a new role.
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
- Molecular classification of Thyroid nodules by cytology.
- Outcomes of pheochromocytoma management in the laparoscopic era.
- Evaluation and management of incidental thyroid nodules in patients with anOther primary malignancy.
- Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
- BAY 43-9006 inhibition of oncogenic RET mutants.
- BRAF is a therapeutic target in aggressive Thyroid carcinoma.
- Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in Tumor cells and tyrosine kinases VEGFR/PDGFR in Tumor vasculature.
- Intraoperative Parathyroid hormone levels in thyroid surgery are predictive of postoperative hypoParathyroidism and need for vitamin D supplementation.
- BAY 43-9006 exhibits broad spectrum oral antiTumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in Tumor progression and angioge...
- An algorithm to maximize use of minimally invasive Parathyroidectomy.
- Major depression due to primary Hyperparathyroidism: a frequent and correctable disorder.
- Location, location, location: finding the elusive Parathyroid.
- SAR of a novel ''Anthranilamide Like'' series of VEGFR-2, multi protein kinase inhibitors for the treatment of Cancer.
- Role of Raf kinase in Cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
- Sorafenib (BAY 43-9006) inhibits Tumor growth and vascularization and induces Tumor apoptosis and hypoxia in RCC xenograft models.
- Utilization of preoperative patient factors to predict postoperative vitamin D deficiency for patients undergoing gastric bypass.
- Editorial review of "Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 RET germline mutations".
- Sorafenib blocks the RAF/MEK/ERK pathway, inhibits Tumor angiogenesis, and induces Tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
- Discovery and development of sorafenib: a multikinase inhibitor for treating Cancer.
- BAY 43-9006: preclinical data.
- Recent advances in the research and development of RAF kinase inhibitors.
- Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
Schools
University Of Cincinnati College Of Medicine
University Hospital Of Cleveland
University Hospital Of Cleveland Case Western Reserve University
Rush Presbyterian St Luke39s Med Center
Procedures Preformed
- Adrenalectomy
- Appendectomy, Laparoscopic
- Appendectomy, Open
- Colectomy
- View All
Conditions Treated
- Adrenal Gland Cancer
- Anorectal Abscess
- Appendicitis
- Atelectasis
- View All
Doctors Specialties
Accepted Insurances
Awards
- Regional Top Doctor
- Fellow (FACS)
Education
-
Case Western Reserve University - University Hospitals
-
University of Cincinnati College of Medicine
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER |
|
1962422675 |
| NPPES Provider LastName |
|
WILHELM |
| NPPES Provider FirstName |
|
SCOTT |
| NPPES Provider ZIPCode |
|
441061716 |
| NPPES Provider State |
|
OH |
| Specialty Description |
|
General Surgery |
| Total Claim Count |
|
46.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1962422675 |
| Last Name Of The Provider |
WILHELM |
| First Name Of The Provider |
SCOTT |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.